Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection.

摘要

Treatment of Crohn's disease with infliximab is an important drug therapy for patients with refractory and fistulating disease. There are concerns over its use in a proportion of Crohn's patients with concurrent hepatitis C infection, since there are theoretical risks of accelerated hepatic decompensation due to the immunomodulatory impact of infliximab. We report a patient with both Crohn's disease and ongoing active hepatitis C infection who underwent infliximab therapy, with no worsening of his liver function or PCR status.